Literature DB >> 30996334

LRSAM1 variants and founder effect in French families with ataxic form of Charcot-Marie-Tooth type 2.

Alessia Peretti1,2, Maud Perie3, Didier Vincent4, Françoise Bouhour5, Klaus Dieterich6, Martial Mallaret7, Fanny Duval8, Cyril Goizet9,10, Raul Juntas-Morales11, Laurent Magy12, Guilhem Solé8, Sylvain Nollet13, Adeline Not14,15, Sarah Léonard-Louis16, Bruno Francou17, Eric Leguern18,19, Anne-Sophie Lia20, Corinne Magdelaine20, Philippe Latour21, Tanya Stojkovic16.   

Abstract

Currently only 25-30% of patients with axonal forms of Charcot-Marie-Tooth disease (CMT) receive a genetic diagnosis. We aimed to identify the causative gene of CMT type 2 in 8 non-related French families with a distinct clinical phenotype. We collected clinical, electrophysiological, and laboratory findings and performed genetic analyses in four different French laboratories. Seventy-two patients with autosomal dominant inheritance were identified. The disease usually started in the fourth decade and the clinical picture was dominated by sensory ataxia (80%), neuropathic pain (38%), and length-dependent sensory loss to all modalities. Electrophysiological studies showed a primarily axonal neuropathy, with possible isolated sensory involvement in milder phenotypes. Disease severity varied greatly but the clinical course was generally mild. We identified 2 novel variants in LRSAM1 gene: a deletion of 4 amino acids, p.(Gln698_Gln701del), was found in 7 families and a duplication of a neighboring region of 10 amino acids, p.(Pro702_Gln711dup), in the remaining family. A common haplotype of ~450 kb suggesting a founder effect was noted around LRSAM1 in 4 families carrying the first variant. LRSAM1 gene encodes for an E3 ubiquitin ligase important for neural functioning. Our results confirm the localization of variants in its catalytic C-terminal RING domain and broaden the phenotypic spectrum of LRSAM1-related neuropathies, including painful and predominantly sensory ataxic forms.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30996334      PMCID: PMC6777460          DOI: 10.1038/s41431-019-0403-8

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  25 in total

1.  A case of CMT 1B due to Val 102/fs null mutation of the MPZ gene presenting as hyperCKemia.

Authors:  M Luigetti; A Modoni; R Renna; G Silvestri; E Ricci; N Montano; G Tasca; M Papacci; M Monforte; A Conte; M G Pomponi; M Sabatelli
Journal:  Clin Neurol Neurosurg       Date:  2010-05-26       Impact factor: 1.876

2.  NEFL E396K mutation is associated with a novel dominant intermediate Charcot-Marie-Tooth disease phenotype.

Authors:  José Berciano; Antonio García; Kristien Peeters; Elena Gallardo; Els De Vriendt; Ana L Pelayo-Negro; Jon Infante; Albena Jordanova
Journal:  J Neurol       Date:  2015-04-01       Impact factor: 4.849

Review 3.  Diagnosis, natural history, and management of Charcot-Marie-Tooth disease.

Authors:  Davide Pareyson; Chiara Marchesi
Journal:  Lancet Neurol       Date:  2009-07       Impact factor: 44.182

4.  Structure of parkin reveals mechanisms for ubiquitin ligase activation.

Authors:  Jean-François Trempe; Véronique Sauvé; Karl Grenier; Marjan Seirafi; Matthew Y Tang; Marie Ménade; Sameer Al-Abdul-Wahid; Jonathan Krett; Kathy Wong; Guennadi Kozlov; Bhushan Nagar; Edward A Fon; Kalle Gehring
Journal:  Science       Date:  2013-05-09       Impact factor: 47.728

5.  A novel LRSAM1 mutation is associated with autosomal dominant axonal Charcot-Marie-Tooth disease.

Authors:  Paschalis Nicolaou; Carlo Cianchetti; Anna Minaidou; Giovanni Marrosu; Eleni Zamba-Papanicolaou; Lefkos Middleton; Kyproula Christodoulou
Journal:  Eur J Hum Genet       Date:  2012-07-11       Impact factor: 4.246

6.  Gene expression profiling of R6/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington's disease.

Authors:  Bin Tang; Tamara Seredenina; Giovanni Coppola; Alexandre Kuhn; Daniel H Geschwind; Ruth Luthi-Carter; Elizabeth A Thomas
Journal:  Neurobiol Dis       Date:  2011-02-18       Impact factor: 5.996

7.  A novel missense mutation of CMT2P alters transcription machinery.

Authors:  Bo Hu; Sezgi Arpag; Stephan Zuchner; Jun Li
Journal:  Ann Neurol       Date:  2016-09-27       Impact factor: 10.422

8.  Mutation in the gene encoding ubiquitin ligase LRSAM1 in patients with Charcot-Marie-Tooth disease.

Authors:  Duane L Guernsey; Haiyan Jiang; Karen Bedard; Susan C Evans; Meghan Ferguson; Makoto Matsuoka; Christine Macgillivray; Mathew Nightingale; Scott Perry; Andrea L Rideout; Andrew Orr; Mark Ludman; David L Skidmore; Timothy Benstead; Mark E Samuels
Journal:  PLoS Genet       Date:  2010-08-26       Impact factor: 5.917

9.  Loss of the E3 ubiquitin ligase LRSAM1 sensitizes peripheral axons to degeneration in a mouse model of Charcot-Marie-Tooth disease.

Authors:  Laurent P Bogdanik; James N Sleigh; Cong Tian; Mark E Samuels; Karen Bedard; Kevin L Seburn; Robert W Burgess
Journal:  Dis Model Mech       Date:  2013-03-08       Impact factor: 5.758

10.  Molecular diagnosis of inherited peripheral neuropathies by targeted next-generation sequencing: molecular spectrum delineation.

Authors:  Juliette Bacquet; Tanya Stojkovic; Amandine Boyer; Nathalie Martini; Frédérique Audic; Brigitte Chabrol; Emmanuelle Salort-Campana; Emilien Delmont; Jean-Pierre Desvignes; Annie Verschueren; Shahram Attarian; Annabelle Chaussenot; Valérie Delague; Nicolas Levy; Nathalie Bonello-Palot
Journal:  BMJ Open       Date:  2018-10-28       Impact factor: 2.692

View more
  2 in total

Review 1.  LRSAM1 and the RING domain: Charcot-Marie-Tooth disease and beyond.

Authors:  Kristien Peeters; Albena Jordanova; Paulius Palaima; José Berciano
Journal:  Orphanet J Rare Dis       Date:  2021-02-10       Impact factor: 4.123

2.  C698R mutation in Lrsam1 gene impairs nerve regeneration in a CMT2P mouse model.

Authors:  Daniel Moiseev; Zafar Wazir; Donghao Liu; Jun Li; Bo Hu
Journal:  Sci Rep       Date:  2022-07-16       Impact factor: 4.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.